Jounce Therapeutics News

JNCEDelisted Stock  USD 1.88  0.00  0.00%   
About 56% of Jounce Therapeutics' investor base is looking to short. The analysis of current outlook of investing in Jounce Therapeutics suggests that many traders are alarmed regarding Jounce Therapeutics' prospects. The current market sentiment, together with Jounce Therapeutics' historical and current headlines, can help investors time the market. In addition, many technical investors use Jounce Therapeutics stock news signals to limit their universe of possible portfolio assets.
  
few days ago at apnews.com         
Casino workers who want smoking ended demonstrate in New Jersey
Macroaxis News: apnews.com
few days ago at independent.co.uk         
Veteran journalist Ken Reid dies aged 69, family says
news
six days ago at thestar.com         
Wisconsin Democrats reelect Neubauer as Assembly minority leader
news
few days ago at bbc.co.uk         
School meals Plans for universal free school meals in NI
news
six days ago at zacks.com         
FATE Presents Encourgaing Data From Lupus Study, Stock Gains
zacks News
over a month ago at www.macroaxis.com         
Acquisition by Tregoning Kathleen of 35604 shares of Spero Therapeutics at 1.52 subject to Rule 16b-...
Macroaxis News
over three weeks ago at bizjournals.com         
Cambridge biotech pulls plug on lung disease drug, cuts percent of workforce
bizjournals News
over a week ago at thelincolnianonline.com         
Achilles Therapeutics plc Shares Bought by BML Capital Management LLC
news
over two months ago at finance.yahoo.com         
Is Achilles Therapeutics Stock Outpacing Its Medical Peers This Year?
Yahoo News
over two months ago at seekingalpha.com         
Achilles stock climbs on strategic focus
seekingalpha News
six days ago at gurufocus.com         
Achilles Therapeutics Receives Approval to Transfer to Nasdaq Capital Market
Gurufocus Stories at Macroaxis
over a week ago at seekingalpha.com         
Instil Bio files for 200M mixed securities shelf
seekingalpha News
over two weeks ago at globenewswire.com         
INVITATION TIL DFDS 3. KVT. 2024 TELEKONFERENCE
Macroaxis News: globenewswire.com
over a month ago at news.google.com         
Baird maintains price target on Instil Bio stock, stays upbeat - Investing.com
Google News at Macroaxis
over two months ago at www.macroaxis.com         
Acquisition by Bronson Crouch of 50000 shares of Instil Bio at 66.1 subject to Rule 16b-3
Macroaxis News
over a year ago at marketwatch.com         
Neoleukin Therapeutics Shares Rise Premarket on Reverse Merger Deal NLTX
marketwatch News
six days ago at zacks.com         
CHMP Endorses AstraZenecas Tagrisso for Expanded Use in NSCLC
zacks News
over a week ago at investing.com         
CytomX Therapeutics SWOT analysis biotech stocks potential in cancer treatment
Investing News at Macroaxis
over a month ago at finance.yahoo.com         
Alphina Therapeutics Appoints Veteran Biotech Executive, Nick Galli, as Chief Executive Officer
Yahoo News
over a week ago at gurufocus.com         
Logos Global Management LP Reduces Stake in NextCure Inc
Gurufocus Stories at Macroaxis
over two weeks ago at news.google.com         
NextCure to Discuss Innovative Cancer Therapies - TipRanks
Google News at Macroaxis
over a month ago at globenewswire.com         
NextCure to Give Two Presentations at Society for Immunotherapy of CancerAnnual Meeting
Macroaxis News: globenewswire.com
few days ago at www.macroaxis.com         
Acquisition by Feigal Ellen of 14250 shares of NextCure subject to Rule 16b-3
Macroaxis News
over a week ago at investing.com         
Nuvation Bios SWOT analysis taletrectinib drives stock potential amid challenges
Investing News at Macroaxis
over two weeks ago at seekingalpha.com         
Nuvation Bio GAAP EPS of -0.15, revenue of 0.7M
seekingalpha News
over a month ago at simplywall.st         
Robert Mashal Spends US220k On Nuvation Bio Shares
Simply Wall St News at Macroaxis
over a month ago at www.macroaxis.com         
Acquisition by Mashal Robert of tradable shares of Nuvation Bio at 2.195 subject to Rule 16b-3
Macroaxis News
Far too much social signal, news, headlines, and media speculation about Jounce Therapeutics that are available to investors today. That information is available publicly through Jounce media outlets and privately through word of mouth or via Jounce internal channels. However, regardless of the origin, that massive amount of Jounce data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Jounce Therapeutics news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Jounce Therapeutics relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Jounce Therapeutics' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Jounce Therapeutics alpha.

Jounce Therapeutics Performance against Dow Jones

 Price Growth (%)  
       Timeline  
1
Stocks to Watch eBay, Etsy, Jounce Therapeutics, Dutch Bros, Cheesecake Factory
02/22/2023
2
Jounce Therapeutics Inc expected to post a loss of9cents a share - Earnings Preview
02/24/2023
3
Why Is Boxed Stock Down 41 percent Today
03/15/2023
4
JNCE STOCK ALERT Halper Sadeh LLC Is Investigating Whether the Sale of Jounce Therapeutics, Inc. Is Fair to Shareholders
03/27/2023
5
Jounce Up 21 percent on Accepting Concentras Buyout Offer
03/28/2023
6
Millennium Partners, L.P. UK Regulatory Announcement Form 8.3 ... - ACROFAN USA
03/30/2023
7
Termination of Proposed Business Combination of Jounce Therapeutics, Inc. and Redx Pharma plc
04/03/2023
8
Jounce Therapeutics, Inc. Short Interest Down 11.4 percent in April
05/01/2023
9
Jounce Therapeutics Announces Closing of Tender Offer
05/04/2023
Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators.
You can also try the Portfolio Backtesting module to avoid under-diversification and over-optimization by backtesting your portfolios.

Other Consideration for investing in Jounce Stock

If you are still planning to invest in Jounce Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Jounce Therapeutics' history and understand the potential risks before investing.
Portfolio Optimization
Compute new portfolio that will generate highest expected return given your specified tolerance for risk
Portfolio Suggestion
Get suggestions outside of your existing asset allocation including your own model portfolios
AI Portfolio Architect
Use AI to generate optimal portfolios and find profitable investment opportunities
Transaction History
View history of all your transactions and understand their impact on performance
Companies Directory
Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals
Portfolio Diagnostics
Use generated alerts and portfolio events aggregator to diagnose current holdings
Idea Optimizer
Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio
Performance Analysis
Check effects of mean-variance optimization against your current asset allocation
Portfolio Anywhere
Track or share privately all of your investments from the convenience of any device